Neurocrine closed at
The company is expanding its work force, not just for Ingrezza, but to bolster its productive research and development unit, said
Gorman said the company is hiring a field sales force to market Ingrezza, which is approved for tardive dyskinesia. And other hires are planned in connection with the launch.
“We'll have approximately 140 reps in the field, two zone managers that take care of eastern and western
The sales reps, who are now being trained, should be in the field within two to three weeks.
Neurocrine started 2016 with about 115 people, nearly all in
“We have plans to increase the onsite staff here at Neurocrine by about 30-35 more people in the remaining eight months of this year,” Gorman said.
Some of those people will be IT and human resources people to support the increased payroll, he said.
“We're also continuing to hire and bolster our internal R&D,” he said. “This drug, Ingrezza, and also our drug for women's health, elagolix, that we have with our partner
“That's been a very productive research engine, going after very difficult to drug targets in difficult diseases, so we continue to invest in there,” Gorman said. “So we'll be hiring more chemists, we'll be hiring more biologists, we're hiring more clinical researchers.”
In February, Neurocrine announced another corporate partnership, with Portuguese drug maker Bial, to in-license a Parkinson's drug, opicapone, sold in
Bial's drug was approved in
“And now we're collaborating with them to develop it and get it registered in
That staffing will be in addition to those to be hired for the Ingrezza launch, Gorman said.
(c)2017 The San Diego Union-Tribune
Visit The San Diego Union-Tribune at www.sandiegouniontribune.com
Distributed by Tribune Content Agency, LLC.